These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 57505)

  • 1. Variable response to long-term 1alpha-hydroxycholecalciferol in haemodialysis osteodystrophy.
    Pierides AM; Ellis HA; Simpson W; Dewar JH; Ward MK; Kerr DN
    Lancet; 1976 May; 1(7969):1092-5. PubMed ID: 57505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histopathology of renal osteodystrophy with particular reference to the effects of 1alpha-hydroxyvitamin D3 in patients treated by long-term haemodialysis.
    Ellis HA; Pierides AM; Feest TG; Ward MK; Kerr DN
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():31s-38s. PubMed ID: 606422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of 1alpha-hydroxyvitamin D3 in pre-dialysis renal bone disease.
    Pierides AM; Ellis HA; Simpson W; Cook D; Kerr DN
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():109s-116s. PubMed ID: 606409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of small doses of 1,25-dihydroxycholecalciferol in renal osteodystrophy.
    Ahmed KY; Varghese Z; Wills MR; Meinhard EA; Moorhead JF
    Lancet; 1978 Mar; 1(8065):629-32. PubMed ID: 76168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with 1,25-dihydroxycholecalciferol therapy in undergoing hemodialysis patients with progressive vitamin D2-treated osteodystrophy.
    Prior JC; Cameron EC; Ballon HS; Lirenman DS; Moriarty MV; Price JD
    Am J Med; 1979 Oct; 67(4):583-9. PubMed ID: 386792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors influencing the response to 1alpha-hydroxyvitamin D3 in patients with renal bone disease.
    Kanis JA; Russell RG; Naik RB; Earnshaw M; Smith R; Heynen G; Woods CG
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():51s-57s. PubMed ID: 606425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1 alpha-hydroxycholecalciferol in hemodialysis renal osteodystrophy. Adverse effects of anticonvulsant therapy.
    Pierides AM; Kerr DN; Ellis HA; Peart KM; O'Riordan JL; DeLuca HF
    Clin Nephrol; 1976 Apr; 3(2):189-96. PubMed ID: 819195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodialysis bone disease: correlation between clinical, histologic, and other findings.
    Alvarez-Ude F; Feest TG; Ward MK; Pierides AM; Ellis HA; Peart M; Simpson W; Weightman D; Kerr DN
    Kidney Int; 1978 Jul; 14(1):68-73. PubMed ID: 682426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteomalacia in patients with chronic renal failure before dialysis or transplantation.
    Mora Palma FJ; Ellis HA; Cook DB; Dewar JH; Ward MK; Wilkinson R; Kerr DN
    Q J Med; 1983; 52(207):332-48. PubMed ID: 6647748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effects of 1,25-dihydroxyvitamin D3 in uremic patients with overt osteodystrophy.
    Brickman AS; Coburn JW; Sherrard DJ; Wong EG; Norman AW; Singer FR
    Contrib Nephrol; 1980; 18():29-41. PubMed ID: 7353378
    [No Abstract]   [Full Text] [Related]  

  • 11. 1alpha-Hydroxycholecalciferol in renal osteodystrophy.
    Pierides AM; Ellis HA; Ward MK; Simpson W; Kerr DN
    Calcif Tissue Res; 1977 May; 22 Suppl():105-11. PubMed ID: 912511
    [No Abstract]   [Full Text] [Related]  

  • 12. Osteomalacic dialysis osteodystrophy: a trial of phosphate-enriched dialysis fluid.
    Feest TG; Ward MK; Ellis HA; Aljama P; Kerr DN
    Br Med J; 1978 Jan; 1(6104):18-20. PubMed ID: 620130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure.
    Andress DL; Norris KC; Coburn JW; Slatopolsky EA; Sherrard DJ
    N Engl J Med; 1989 Aug; 321(5):274-9. PubMed ID: 2631697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological activity of endogenous and exogenous calcitonin in patients with osteitis fibrosa and chronic renal failure.
    Cundy T; Heynen G; Paton S; Ledingham JG; Russell RG; Oliver DO; Kanis JA
    Proc Eur Dial Transplant Assoc; 1978; 15():524-31. PubMed ID: 740683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone disease and hyperparathyroidism in chronic renal failure: the effect of 1alpha-hydroxyvitamin D3.
    Peacock M; Aaron JE; Walker GS; Davison AM
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():73s-81s. PubMed ID: 606428
    [No Abstract]   [Full Text] [Related]  

  • 16. The clinical spectrum of renal osteodystrophy in 57 chronic hemodialysis patients: a correlation between biochemical parameters and bone pathology findings.
    Chazan JA; Libbey NP; London MR; Pono L; Abuelo JG
    Clin Nephrol; 1991 Feb; 35(2):78-85. PubMed ID: 2019018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of 6 months therapy with 1,25 (OH)2D3 on bone disease of dialysis patients.
    Malluche HH; Goldstein DA; Massry SG
    Contrib Nephrol; 1980; 18():98-104. PubMed ID: 7353383
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of uremic osteopathy. Effects of vitamin D metabolites and vitamin D analogs in chronic uremia and experimental renal insufficiency].
    von Herrath D; Kraft D; Schaefer K; Krempien B
    MMW Munch Med Wochenschr; 1974 Sep; 116(37):1573-8. PubMed ID: 4374654
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of bone mineral content determination in the evaluation of osteodystrophy among hemodialysis patients.
    Heaf JG; Nielsen LP; Mogensen NB
    Nephron; 1983; 35(2):103-7. PubMed ID: 6621754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of 1,25(OH)2-vitamin D3 to separate 'types' on renal osteodystrophy.
    Coburn JW; Brickman AS; Sherrard DJ; Singer FR; Wong EG; Baylink DJ; Norman AW
    Proc Eur Dial Transplant Assoc; 1977; 14():442-50. PubMed ID: 600961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.